Kipp ConradKipp Conrad
|
 |
Imiquimod ( Aldara ) 5% cream is an effective therapeutic option for both sBCC and nBCC in patients with basal cell nevus syndrome. Initially used antibiotics over a test area and then over the whole of the lesion, for a total of 7 months, the Imiquimod ( Aldara ) cream resulted in complete clinical and histological cure. Conventional surgery using a 5-10 mm margin is the recommended treatment; however, lesions can be quite large and surgical removal may involve general plastic repair. The patient has been follo up for 9 months without evidence of recurrence. Topical Imiquimod ( Aldara ) treatment of superficial and antibiotics nodular basal cell carcinomas in patients affected by basal cell nevus syndrome. A preliminary report.BACKGROUND. Moreover, DNA image cytometry open DNA aneuploidy (an indicator of prospective malignancy) in pretreatment samples but not in post-treatment samples. Imiquimod ( Aldara ). The treatment was very well received by all patients engaged in the study, who stated their appreciation for a topical treatment rather than multiple surgical excisions. We report a 55-year-old non-immunocompromised woman with extensive, human papillomavirus (HPV) 16-positive anogenital Bowen's disease. Three sBCCs cleared clinically amoxicillin 500 after 4 weeks of treatment and two nBCCs after 8 weeks. We tried topical Imiquimod ( Aldara ) 5% cream (Aldara), a local immunomodulator, which has recently become available for the treatment of external genital and perianal warts. valtrex The remaining four lesions sho excellent clinical responses with evident (>50%) size reduction at 6 weeks, but no further improvement. Imiquimod ( Aldara ) 5% cream has been shown to be effective in the treatment of superficial basal cell carcinomas amoxicillin 400 (sBCCs). Treatment consisted for sBCCs of three weekly applications and for nBCCs of five weekly applications for 8 weeks. A novel treatment for lentigo maligna.Lentigo maligna is the in situ phase of lentigo maligna melanoma, and if left untreated it may progress to invasive melanoma. Follow-up was performed at 1-week intervals in order to carefully detect any change. We report an elderly patient with a large lentigo maligna on the scalp who was reluctant to have surgery. After 5 months of local treatment with Imiquimod ( Aldara ), the lesions completely regressed clinically and histologically, and HPV 16 DNA was no longer detectable. For small tumors, similar-appearing lesions were removed for baseline histological confirmation. A higher number of applications and longer treatment periods are required for nBCCs.. No systemic side effects were noted. To evaluate the efficacy, safety and compliance of Imiquimod ( Aldara ) 5% cream for the treatment of sBCCs and nodular BCCs (nBCCs) in patients affected by basal cell nevus syndrome. Histological examination with multiple-step sections confirmed complete clearing for those lesions showing clinical resolution, except for one nBCC that sho scant tumor remnants. Three patients (two male, one female) were enrolled in the study. Nine tumors (five sBCCs and four nBCCs), all ranging in size from 0.5 cm to 1 cm, were treated. Successful treatment of anogenital Bowen's disease with the immunomodulator Imiquimod ( Aldara ), and monitoring of therapy by DNA image cytometry.Imiquimod ( Aldara ) (Aldara, 3M) is an immune response modifier used for the treatment of anogenital warts. Local adverse effects (itching, erythema and bleeding) were mild and did not prompt discontinuation of treatment. Histological examination was performed at the beginning and at the end of the study. It most commonly occurs on the exposed sites of the face and neck of middle-aged or elderly patients. Therefore, Imiquimod ( Aldara ) might be a treatment option for Bowen's disease, particularly in patients where other treatment modalities such as surgery are contraindicated.
|